Skip to Content

What types of Hepatitis C does Mavyret treat?

Answers (1)

Official Answer by Drugs.com 10 Oct 2017

Mavyret (glecaprevir and pibrentasvir) from AbbVie is an 8 week oral treatment for all chronic hepatitis C virus (HCV) genotypes (1-6) in adult patients without cirrhosis (liver disease) who have not received previous treatments. Standard treatment length for HCV was previously 12 weeks or more. Mavyret inhibits NS3/4A protease and pibrentasvir inhibits NS5A.

Mavyret is FDA-approved for two patient populations: either chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), or adult patients with HCV genotype 1 infection, previously treated with an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both. Studies demonstrated that 92 to 100 percent of patients had no virus detected in the blood 12 weeks after finishing treatment, suggesting a cure. The most commonly reported adverse reactions (> 10%) are headache and fatigue.

Votes: +0
Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What is the difference between Biktarvy and Descovy?

Posted 7 Mar 2018 1 answerFAQ by Drugs.com

What is the difference between Symdeko and Orkambi?

Posted 7 Mar 2018 1 answerFAQ by Drugs.com